Drug Trial Radar · NCT03138512
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,641
Actual
Start
Jul 7, 2017
Primary completion
Sep 28, 2023
Study completion Feb 1, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 3, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.
Conditions
- Carcinoma, Renal Cell
Interventions
nivolumabBiological
Specified dose on specified days
ipilimumabBiological
Specified dose on specified days
nivolumab placeboDrug
Specified dose on specified days
ipilimumab placeboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS) by BICR - Treatment Part A and BTime frame: From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)
Locations
200 sites in 25 countries. Site status is shown where the registry gives one.
Local Institution - 0019
Birmingham, Alabama
Local Institution - 0056
Springdale, Arkansas
Local Institution - 0186
Los Angeles, California
Local Institution - 0180
Los Angeles, California
Local Institution - 0002
San Francisco, California
Local Institution - 0185
Aurora, Colorado
Local Institution - 0016
Athens, Georgia
Local Institution - 0005
Chicago, Illinois
Local Institution
Chicago, Illinois
Local Institution - 0006
St Louis, Missouri
Local Institution - 0012
Howell Township, New Jersey
Local Institution - 0007
Buffalo, New York
Local Institution - 0181
New York, New York
Local Institution - 0001
New York, New York
Local Institution - 0008
Columbus, Ohio
Local Institution - 0009
Portland, Oregon
Local Institution - 0010
Allentown, Pennsylvania
Local Institution - 0014
Greenville, South Carolina
Local Institution - 0013
Chattanooga, Tennessee
Local Institution - 0183
Nashville, Tennessee
Local Institution - 0057
Fairfax, Virginia
Local Institution - 0179
Buenos Aires, Argentina
Local Institution - 0099
CABA, Argentina
Local Institution - 0096
Córdoba, Argentina
Local Institution - 0098
Córdoba, Argentina
Local Institution - 0164
San Juan, Argentina
Local Institution - 0097
San Miguel de Tucumán, Argentina
Local Institution - 0178
Capital Federal, Buenos Aires, Argentina
Local Institution - 0126
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0203
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0095
Mar del Plata, Buenos Aires, Argentina
Local Institution - 0208
Mar del Plata, Buenos Aires, Argentina
Local Institution - 0173
Río Cuarto, Córdoba Province, Argentina
Local Institution - 0232
Bariloche, Río Negro Province, Argentina
Local Institution - 0215
Macquarie Park, New South Wales, Australia
Local Institution - 0032
Northmead, New South Wales, Australia
Local Institution - 0036
Randwick, New South Wales, Australia
Local Institution - 0035
St Leonards, New South Wales, Australia
Local Institution - 0113
South Brisbane, Queensland, Australia
Local Institution - 0213
Southport, Queensland, Australia
Showing 40 of 200 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.